Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences:

• H.C. Wainwright 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026
  • Company fireside chat starting at 3:30 p.m. ET
• 2026 RBC Capital Markets Global Healthcare Conference: Wednesday, May 20, 2026
  • Company fireside chat starting at 1:35 p.m. ET

The fireside chats will be webcast live and can be accessed by visiting the Investors section of Mirum’s corporate website. The archived webcasts will be available for replay.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260512832191/en/

Investor Contact:
Andrew McKibben
[email protected]

Media Contact:
Meredith Kiernan
[email protected]

Source: Mirum Pharmaceuticals, Inc.

You May Also Be Interested In

• Destiny Tech100 Inc. Reports Second Quarter 2026 Results
• 24 Greenberg Traurig Attorneys, 11 Practices Recognized in 2027 Edition of Latin Lawyer 250
• HORROR HAS A NEW HOME: HOUSE OF HORROR HAUNTED CARNIVAL MARKS 25 YEARS AT TROPICAL PARK